

Hydroxychloroquine

Primary Information Services

[Home](#) . [Pharmaceutical Industry](#) . [Ordering Information](#) . [Contact](#)

Search PrimaryInfo

Project @ a Glance

Information profile @ a Glance

- Hydroxychloroquine, sold under the brand name Plaquenil among others, is a medication used to prevent and treat malaria in areas where malaria remains sensitive to chloroquine. Other uses include treatment of rheumatoid arthritis, lupus, and porphyria cutanea tarda. It is taken by mouth
- Hydroxychloroquine is in a class of drugs called antimalarials. It is used to prevent and treat acute attacks of malaria. It is also used to treat discoid or systemic lupus erythematosus and rheumatoid arthritis in patients whose symptoms have not improved with other treatments
- Only limited clinical trial data available to date to evaluate use of hydroxychloroquine for treatment or

Contents

Basics

- Treatment of COVID-19 Infection- A Systematic Literature Review
- Pharmacology of Hydroxychloroquine
- Studies underway
- Small Trial
- Shorten time to recovery
- FAQ - COVID Management

Companies

- Global Company
- Company - India
- Exporter of Pharmaceutical Products - India
- Company - Product monograph - Ontario
- Company in the News

Product Information

- Monograph - Hydroxychloroquine Sulfate
- Product Profile

- prevention of COVID-19
- Emergency use authorization (EUA) for hydroxychloroquine: FDA issued an EUA that permits distribution of the drug from the strategic national stockpile (SNS) for use only in adults and adolescents weighing 50 kg or more hospitalized with COVID-19 for whom a clinical trial is not available or participation not feasible
- FDA states that, based on the totality of scientific evidence available, it is reasonable to believe that the drug may be effective in treating COVID-19 and that, when used under the EUA conditions, known and potential benefits outweigh known and potential risks.
- Efficacy measures: Initial studies evaluating hydroxychloroquine based efficacy of the drug on negative conversion in nasopharyngeal samples at day 6 or 7. 7, 18 RT-PCR tests using upper and lower respiratory specimens (including nasopharyngeal and oropharyngeal swabs) are recommended for diagnosis of COVID-19; 19, 21 however, dynamics of SARS-Cov-2 in infected patients (untreated or treated) and presence of the virus at various body sites over the course of infection have not been fully determined.

- Hydroxychloroquine sulfate properties
- Product Characteristics

Technology Information

- Planning of Hydroxychloroquine's Syntheses
- Manufacturing process
- SARS-CoV-2 in vitro
- Clinical Trial - Patients with Dyslipidemia

Usage for COVID-19

- Emergency use authorization
- Advisory on the use of Hydroxychloroquin
- COVID-19 Drug Therapy
- Clinical Trials
- Assessment of Evidence for COVID-19-Related Treatments
- Binding to the SARS-CoV-2 Spike (S)Protein
- Chloroquine-Hydroxychloroquine

Applications

- Study of Hydroxychloroquine & Treatment plan
- Endothelial dysfunction
- Hydroxychloroquine for treating COVID-19
- A Therapeutic Choice in Diabetes Mellitus
- Antiphospholipid Antibody-Induced Inhibition Of Trophoblast Migration
- Effective in inhibiting SARS-CoV-2 infection in vitro

Market Scenario

- The product in focus
- Market Authorization
- Company - Global Supply Chain

- European Advisory
- Consultant - Market reports

[Order the database Today](#)

Primary Information Services
21 Murugappan St, SwamyNagar Ext2,
Ullagaram, Chennai - 600091, India.
Phone: 91 44 22421080 Email :primaryinfo@gmail.com
Mobile numbers:9940043898, 9444008898 Fax :91 44 22423753